Rani Therapeutics Holdings, Inc. - RANI
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G | AWM Investment Company, Inc. | 9.9% | 9,745,343 | View |
| Feb 12, 2026 | SCHEDULE 13G | SymBiosis Capital Partners, LLC | 6.5% | 6,300,000 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.23% | 5,109,368 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Armistice Capital, LLC | 4.99% | 2,515,652 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven Boyd | 4.99% | 2,515,652 | View |
| Oct 30, 2025 | SCHEDULE 13D | — | 9.99% | — | View |
| Oct 30, 2025 | SCHEDULE 13G | RA Capital Management, L.P. | 9.9% | 9,882,477 | View |
| Oct 30, 2025 | SCHEDULE 13G | Peter Kolchinsky | 9.9% | 9,882,477 | View |
| Oct 30, 2025 | SCHEDULE 13G | Rajeev Shah | 9.9% | 9,882,477 | View |
| Oct 30, 2025 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 9.9% | 9,882,477 | View |
| Oct 27, 2025 | SCHEDULE 13D/A | — | — | 22,411,124 | View |
| Oct 23, 2025 | SCHEDULE 13G | Invus Public Equities, L.P. | 8.8% | 8,617,378 | View |
| Oct 23, 2025 | SCHEDULE 13G | Invus Public Equities Advisors, LLC | 8.8% | 8,617,378 | View |
| Oct 23, 2025 | SCHEDULE 13G | Invus Global Management, LLC | 8.8% | 8,617,378 | View |
| Oct 23, 2025 | SCHEDULE 13G | Siren, L.L.C. | 8.8% | 8,617,378 | View |
| Oct 23, 2025 | SCHEDULE 13G | Avicenna Life Sci Master Fund LP | 1.3% | 1,208,533 | View |
| Oct 23, 2025 | SCHEDULE 13G | Avicenna Life Sci Master GP LLC | 1.3% | 1,208,533 | View |
| Oct 23, 2025 | SCHEDULE 13G | Ulys, L.L.C. | 1.3% | 1,208,533 | View |
| Oct 23, 2025 | SCHEDULE 13G | Raymond Debbane | 9.99% | 9,825,911 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.